Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Shifting to a Holistic Approach to Treat Developmental Epileptic Encephalopathies
December 13th 2021The medical director of the Epilepsy program at the University of Toronto discussed her presentation at AES 2021 regarding the need to change how clinicians view and treat patients with developmental epileptic encephalopathies.
Rituximab Shows Minimal Steroid-Sparing Effect in AChR-Ab+ Myasthenia Gravis
December 9th 2021Despite displaying safety, after accounting for baseline differences between groups, statistically significant clinical improvement was not observed in key secondary outcomes, exploratory clinical outcomes, or responder analyses.
NeuroVoices: Jessica Fesler, MD, MEd, on the Need to Improve and Integrate Seizure Tracking Apps
December 8th 2021The staff epileptologist at Cleveland Clinic’s Epilepsy Center discussed the current state of seizure tracking applications, their limitations, and their untapped potential to be integrated in clinical care and with electronic medical records.
The Substantial Costs Affiliated With Alzheimer Drug Development: Jeffrey Cummings, MD, ScD
December 2nd 2021The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts. [WATCH TIME: 3 minutes]
FDA Accepts sNDA, Grants Priority Review to Fenfluramine for Lennox-Gastaut Syndrome
December 1st 2021After demonstrating a significant effect in reducing the frequency of drop seizures, fenfluramine aims to build on its previous indication in rare epileptic disorders, as it is currently approved to treat Dravet syndrome.